The case of eculizumab: litigation and purchases by the Brazilian Ministry of Health.

Rev Saude Publica · 2020 · PMC7017980 · PMID 32130309

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

extremely significantno p-value reported

CONCLUSION Eculizumab represented extremely significant expenditures for the Brazilian Ministry of Health during the period.

also in 7,787 other papers

an increasing trendno p-value reported

There was an increasing trend in the number of purchases and quantities acquired over time.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.